Back to top
more

AMAG Pharmaceuticals, Inc. (AMAG)

(Real Time Quote from BATS)

$10.78 USD

10.78
195,866

+0.08 (0.75%)

Updated Dec 5, 2019 12:33 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | D Growth | D Momentum | B VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Why Is AMAG Pharmaceuticals (AMAG) Up 9.7% Since Last Earnings Report?

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMAG

Zacks Equity Research

Is the Options Market Predicting a Spike in AMAG Pharmaceuticals (AMAG) Stock?

Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.

AMAG

Zacks Equity Research

AMAG Sees Hammer Chart Pattern: Time to Buy?

AMAG Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

AMAG

Zacks Equity Research

AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

AMAG disappoints investors with earnings and sales miss in the third quarter.

AMAG ACOR ANIK BGNE

Zacks Equity Research

AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Lags Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -37.25% and -5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AMAG

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

AMAG AMGN GILD ALXN

Zacks Equity Research

Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.

SNY AMAG AMGN ALXN REGN GILD

Zacks Equity Research

What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?

Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.

AMAG GWPH DCPH VRAY

Zacks Equity Research

AMAG Pharmaceuticals, Inc. (AMAG) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in AMAG Pharmaceuticals, Inc. (AMAG).

AMAG

Zacks Equity Research

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

SNY AMAG AMGN AMRN

Zacks Equity Research

AMAG Pharmaceuticals (AMAG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AMAG Pharmaceuticals (AMAG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMAG

Zacks Equity Research

Why Is AMAG Pharmaceuticals (AMAG) Up 27.3% Since Last Earnings Report?

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMAG

Zacks Equity Research

Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

AMAG CELG ACAD PTN

Zacks Equity Research

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

AMAG CGEN BGNE GH

Zacks Equity Research

AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -93.94% and -15.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AMAG

Zacks Equity Research

AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMAG

Zacks Equity Research

Will AMAG Pharmaceuticals (AMAG) Report Negative Q2 Earnings? What You Should Know

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMAG

Zacks Equity Research

AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?

We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.

AMAG REGN GILD ALXN

Zacks Equity Research

Alexion's Ultomiris Receives EU Approval for PNH in Adults

Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

AMAG ALXN ACHN AKTX

Zacks Equity Research

Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

AMAG CNAT REGN ALXN GILD VRTX

Zacks Equity Research

AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire

AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.

AMAG ACOR AGTC ANIK

Zacks Equity Research

All You Need to Know About AMAG Pharmaceuticals (AMAG) Rating Upgrade to Buy

AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMAG

Zacks Equity Research

TherapeuticsMD Enters Agreement to Market Drugs Outside US

TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.

AGN PFE AMAG TXMD

Zacks Equity Research

AMAG Pharmaceuticals (AMAG) Down 8.9% Since Last Earnings Report: Can It Rebound?

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMAG

Zacks Equity Research

New Strong Sell Stocks for May 20th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

WIRE ENR AMAG NLY AUG